pathophysiology of neurodegenerative diseases. With a team of 50 employees, 4B Technologies is committed to advancing the field of biomedicine through its work on transformative medicines. The company's notable achievements include the development of the FIC monoclonal antibody FB1003, which has received approval from the Alfred Clinical Research Ethics Committee. 4B Technologies aims to tackle the challenges of heterogeneity and the lack of early intervention treatments in central nervous system diseases, striving to make significant clinical benefits a reality for patients worldwide.